Some questions to be raised about the hepatitis B vaccine

Vaccine
J Poirriez

Abstract

The author consider some questions to be more carefully studied about the hepatitis B vaccine: route of injection (subcutaneous or intramuscular), amount of antigen (Ag), adjuvant (necessary or not), antigenic and molecular structure of HBsAg. What is important is to get high seroconversion rates, but not to get very high antibody titers (protective immunity is not dependent of antibody titers). Two types of vaccine could be used, and further studied. Why not use in healthy adults and children low dose vaccines (with 1.5-2.5 microg of HBsAg), possibly without adjuvant, and to be injected subcutaneously? And the 20 microg dose of vaccine could be used intramuscularly only for low- or non-responders, in high risk groups.

References

Nov 17, 1978·Medical Microbiology and Immunology·P MaupasN Geslin
Apr 1, 1988·Journal of Hepatology·W JilgF Deinhardt
Dec 1, 1988·American Journal of Hematology·P M MannucciM Colombo
Oct 21, 1998·The Journal of Infectious Diseases·A P Moran, M M Prendergast
Jul 7, 1999·Vaccine·J Poirriez

❮ Previous
Next ❯

Citations

Sep 11, 2007·Journal of Pharmaceutical Sciences·Chandan ThomasFakhrul Ahsan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.